FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
Links shared publicly online about this topic.
- 418total visits
FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
View full resource at novartis.com
Tags: COPD, COPD Medication, Drug, FDA, Novartis
Most Recently Shared on March 23, 2011 at 3:24 pm By:
#FDA extends regulatory review period for Novartis #COPD drug http://ow.ly/4kMob
Advertisement
